NovelMed Therapeutics, Inc. is structured around developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. Utilizing the firm's proprietary portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with large market potential and unmet medical need.treatments for a range of devastating illnesses to include arthritis, cardiovascular disease, stroke, and cancer. NovelMeds approach is to develop target specific monoclonal antibodies and small molecule therapies to provide maximum benefit to patients suffering from such diseases. Taking advantage of the fact that therapeutic monoclonal antibodies bind to a specific target and neutralizes that function which is apparently responsible for the disease in question. NovelMed has also developed small molecule therapies to provide treatments for multi-etiological disease such as arthritis. Using these two therapeutic approaches, NovelMed has developed a pipeline of products that will ensure maximum therapeutic benefit with the least amount of adverse effects. Operating a fully equipped research laboratory facility, the NovelMed team includes biochemists, molecular biologists, chemists, medicinal chemists, as well as experts in inflammation, cardiovascular, thrombosis, cancer, and FDA regulatory affairs. Specializing in complement-based therapies, over the last decade the firm has generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of NovelMed's humanized antibody platform; an exciting pipeline of therapeutic candidates - a portfolio of therapeutic antibodies target non-orphan and orphan diseases and have the potential for a better safety and efficacy profile than currently marketed drugs
